MOVING FROM CHALLENGES OF HIGH CONCENTRATION PROTEIN FORMULATIONS DEVELOPMENT TO MEET THE NEEDS OF HIGH POTENT BISPECIFICS
March 19, 2019 | (10.00 AM)
USA (United States of America)
Monoclonal antibodies (mAbs) have significantly contributed to the treatment of oncological and immunological disorders over the last two decades. Next advancement in this line is the introduction of bispecific antibodies – molecules which can bind to two different receptors at the same time. Engaging T-cells to target tumor cells and eventually killing tumor cells have been clinically demonstrated by such bispecific antibody. Traditionally one of the key challenges for developing mAbs is to administer high quantities of mAbs, on the other hand, bispecific antibodies are extremely specific and more efficient, which makes them highly potent leading to a reduced dose.